Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Current Leases (2019 - 2025)

Historic Current Leases for Theravance Biopharma (TBPH) over the last 7 years, with Q3 2025 value amounting to $10.9 million.

  • Theravance Biopharma's Current Leases rose 16010.49% to $10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.9 million, marking a year-over-year increase of 16010.49%. This contributed to the annual value of $10.7 million for FY2024, which is 17305.63% up from last year.
  • Theravance Biopharma's Current Leases amounted to $10.9 million in Q3 2025, which was up 16010.49% from $10.9 million recorded in Q2 2025.
  • Theravance Biopharma's Current Leases' 5-year high stood at $10.9 million during Q3 2025, with a 5-year trough of $503000.0 in Q4 2021.
  • Its 5-year average for Current Leases is $5.5 million, with a median of $4.2 million in 2024.
  • Per our database at Business Quant, Theravance Biopharma's Current Leases tumbled by 9490.22% in 2021 and then soared by 130361.27% in 2023.
  • Theravance Biopharma's Current Leases (Quarter) stood at $503000.0 in 2021, then surged by 1242.54% to $6.8 million in 2022, then tumbled by 41.91% to $3.9 million in 2023, then skyrocketed by 173.06% to $10.7 million in 2024, then rose by 1.89% to $10.9 million in 2025.
  • Its Current Leases stands at $10.9 million for Q3 2025, versus $10.9 million for Q2 2025 and $10.8 million for Q1 2025.